GROUP CLASS ACTION: AN EMERGING LEGAL RISK FOR PHARMA BUSINESSES

Keep Reading

Insights

A WAVE OF DISPUTES ON THE HORIZON FOR PHARMA

Michael Frisby and Robert Eriksson of Stevens & Bolton predict that, with the record fines being imposed in the pharmaceutical industry for competition law breaches, life science companies could soon become targets of claimant law firms and litigation funders pursuing group claims.

Before You Go

Never miss a thing in the litigation finance market.